A significant part of his practice involves pharmaceutical patent litigation. Ben has served on trial teams in high-stakes matters and represented clients in inter partes review proceedings before the U.S. Patent and Trademark Office. Beyond contentious matters, he counsels life sciences companies on patent portfolio analysis, due diligence, and freedom-to-operate issues, helping clients evaluate intellectual property risk and make informed decisions about their products and businesses.
His technical training gives Ben a strong foundation for understanding the science underlying pharmaceutical and biotechnology matters. He also recently completed MIT Professional Education program on artificial intelligence in the pharmaceutical industry, expanding his perspective on emerging technologies and their implications for drug development and the life sciences sector.
Before joining Michelman Robinson, Ben developed his practice at law firms with sophisticated intellectual property and life sciences capabilities, beginning his career at an intellectual property boutique focused on pharmaceutical patent litigation. He is also registered to practice before the U.S. Patent and Trademark Office.
Life Sciences
Mining
Real Estate
A significant part of his practice involves pharmaceutical patent litigation. Ben has served on trial teams in high-stakes matters and represented clients in inter partes review proceedings before the U.S. Patent and Trademark Office. Beyond contentious matters, he counsels life sciences companies on patent portfolio analysis, due diligence, and freedom-to-operate issues, helping clients evaluate intellectual property risk and make informed decisions about their products and businesses.
His technical training gives Ben a strong foundation for understanding the science underlying pharmaceutical and biotechnology matters. He also recently completed MIT Professional Education program on artificial intelligence in the pharmaceutical industry, expanding his perspective on emerging technologies and their implications for drug development and the life sciences sector.
Before joining Michelman Robinson, Ben developed his practice at law firms with sophisticated intellectual property and life sciences capabilities, beginning his career at an intellectual property boutique focused on pharmaceutical patent litigation. He is also registered to practice before the U.S. Patent and Trademark Office.
Commercial & Business Litigation
A significant part of his practice involves pharmaceutical patent litigation. Ben has served on trial teams in high-stakes matters and represented clients in inter partes review proceedings before the U.S. Patent and Trademark Office. Beyond contentious matters, he counsels life sciences companies on patent portfolio analysis, due diligence, and freedom-to-operate issues, helping clients evaluate intellectual property risk and make informed decisions about their products and businesses.
His technical training gives Ben a strong foundation for understanding the science underlying pharmaceutical and biotechnology matters. He also recently completed MIT Professional Education program on artificial intelligence in the pharmaceutical industry, expanding his perspective on emerging technologies and their implications for drug development and the life sciences sector.
Before joining Michelman Robinson, Ben developed his practice at law firms with sophisticated intellectual property and life sciences capabilities, beginning his career at an intellectual property boutique focused on pharmaceutical patent litigation. He is also registered to practice before the U.S. Patent and Trademark Office.
Life Sciences
Mining